Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01701830

Enrollment

Registered

2012-10-05

Start date

2012-10-31

Completion date

2013-05-31

Last updated

2012-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Non-diabetic Chronic Kidney Disease

Keywords

omentin-1, carotid atherosclerosis, kidney disease

Brief summary

The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Detailed description

Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion criteria

* Chronic kidney disease of stage 5 * The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization) * Severe heart failure * Stage 2 hypertension * Diabetes mellitus * Corticosteroid therapy * Severe hepatic disease * Smoking * Inflammatory disease * Acute infectious disease * Malignancy

Countries

Turkey (Türkiye)

Outcome results